Publikationen in Fachzeitschriften (ab 2007) 


Bundy BD, Bellemann N, Burkholder I, Heye T, Radeleff BA, Grenacher L, Kauczor HU, Weber MA: Vereinbarkeit von Familie und Beruf: Umfrage unter Radiologen und medizinisch-technischen Angestellten in Kliniken unterschiedlicher Ausrichtung. Der Radiologe, 52(3): 267-276.

Hofheinz RD, Heinemann V., Fischer von Weikersthal L., Laubender RP, Gencer D, Burkholder I, Hochhaus A, Stintzing S: Capecitabine (cape)-associated hand-foot skin reaction (HFS) as a clinical predictor of improved survival in patients (pts) with colorectal cancer. JCO 30: abstr. 3541

Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A: Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol.: 13(6): 579-588

Hofheinz RD, Wenz FK, Post F, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler MH, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Gencer D, Burkholder I, Hochhaus A: Capecitabine (Cape) versus 5-fluorouracil (5-FU)–based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial. . JCO 29: abstr. 3504


Combs SE, Habermehl D, Ganten T, Schmidt J, Edler L, Burkholder I, Jäckel O, Haberer T, Debus J: Phase I study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. BMC Cancer, 12: 67
Combs SE, Edler L, Burkholder I, Rieken S, Habermehl D, Jäckel O, Haberer T, Unterberg A, Wick W, Debus J, Haselmann R: Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial BMC Cancer, 10: 615

Combs SE, Burkholder I, Edler L, Rieken S, Habermehl D, Jäkel O, Haberer T, Haselmann R, Unterberg A, Wick W, Debus J: Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial. BMC Cancer, 10: 533

Weber MA, Henze M, Tüttenberg J, Stieltjes B, Meissner M, Zimmer F, Burkholder I, Kroll A, Combs SE, Vogt-Schaden M, Giesel FL, Zoubaa S, Haberkorn U, Kauczor HU, Essig M: Biopsy Targeting Gliomas: Do Functional Imaging Techniques Identify Similar Target Areas? Invest Radiol: 8 (epub ahead of print)

Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, Bokemeyer C, Schumacher U, Laack: Elevated pretreatment serum concentration of ykl-40 – an independent prognostic biomarker for poor survival in patients with metastatic non-small cell lung cancer. Cancer 116(17): 4114-21.


Winterstein M, Münter MW, Burkholder I, Essig M, Kauczor HU, Weber MA: Partially resected gliomas: Diagnostic performance of fluid attenuated inversion recovery MR imaging for detection of progression. Radiolgogy, 254(3): 907-16.

Schneider K, Schwarz M, Burkholder I, Kopp-Schneider A, Edler E, Kisner-Ovaskainen A, Hartung T, Hoffmann S: "ToxRTool" a new tool to assess the reliability of toxicological data. Toxicokogy letters (2009), 189(2): 138-144.

Hofheinz R, Wenz F, Post S, Matzdorff A, Laechelt S, Mueller L, Link H, Moehler M, Burkholder I, Hochhhaus H: Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo) adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Safety results of a randomized, phase III trial.JCO (2009) 27: 15s: abstr. 4014

Thöm I, Schult-Kronefeld I, Burkholder I, Schuch G, Andritzky B, Kastendieck H, Edler L, Wagner C, Bokemeyer C, Schumacher U, Laack E: Expression of CEACAM - 1 in pulmonary adenocarcinomas and their metastases. Anticancer Res. (2009): 29(1) 249-254.

Thoem I, Johansen JS, Andritzky B, Schuch H, Burkholder I, Edler K, Bokemeyer C Schumacher U, Laack E: Elevated pretreatment serum treatment serum concentration of YKL-40 – An independent prognostic biomarker for poor survival in patients with metastatic non-small cell lung cancer.JCO (2008), 26 abstract 19044. Onkologie (2008), 31 (4) 185-189.

Goern M, Habermann CR, Anige M, Thöm I, Schuch G, Andritzky B, Brandl S, Burkholder I, Edler L, Hossfeld DK, Bokemeyer C, Laack E: A pilot study of docetaxel and trafosfamide as second-line "metronomic" chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Onkologie (2008), 31(4), 185-189.

Sangrajran S, Schmezer P, Bukrholder I, Waas P, Boffetta P, Brennan P, Bartsch H, Wiagnon S, Popanda O: Polymorphismus in three base excision repair genes and brest cancer risk in Thai women. Breast Cancer Res. Treat. (2007), epub.

Burkholder I: Adjuvante Therapien beim Kolonkarzinom: Einigung über Definition und Verwendung von alternativen Endpunkten(KOMMENTAR) InFoOnkologie 10 (6) 396-397 (2007)

Steinbild S, Mross K, Frost A, Morant R, Gillessen S, Dittrich C, Strumberg d, Hochhaus A, Hanauske A, Edler L, Burkholder I, Scheuen M: A clinical phase II study with Sorafenib in patients with hormone-refractory prostate cancer – a study of the CESAR Central European Society for Anticancer Drug Research-EWIV,British Journal of Cancer 97 1480-1485 (2007)

Wunder C,Burkholder I: PSA-Verdopplungszeit: Kleine Änderungen bei der Berechnung haben weitreichende Konsequenzen(KOMMENTAR) InFoOnkologie 10 (5) 347-348 (2007)

Sangrajran S, Schmezer P, Bukrholder I, Boffetta P, Brennan P, Woelfelschneider A, Bartsch H, Wiagnon S, Cheisilpa A, Popanda O: The XRCC3 Thr241Met polymorphismus and breast cancer risk; a case-control study in a Thai population. Biomarkers (2007), 12(5), 523-532.

Andritzky B, Adler S, Burkholder I, Thöm I, Schuch G, Görn M, Schilling G, Edler L, Bokemeyer C, Laack E: Analysis of 94 patients with advanced biliary tract cancer.Journal of Clinical Oncology Vol. 25 (18S): 15172 (2007)

Goern M, Habermann C, Thöm I, Schuch G, Andritzky B, Brandl S, Burkholder I, Edler L, Hossfeld DK, Bokemeyer C, Laack E: A pilot study of weekly docetaxel and daily trafosfamide as metronomic second-line chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). JCO (2007), 25 (18S), 18105.

Burkholder I.:Surrogat-Endpunkte sind kritischer zu definieren und auszuwählen(KOMMENTAR). InFoOnkologie 10 (3) 172-173 (2007)

Laack E, Thoem I, Krull A, Engel-Rieder W, Mueller T, Meissner C, Durk H, Fischer J, Gutz S, Kortsik C, Elbers M, Schuch G, Andritzky B, Born B, Burkholder I, Edler L, Hossfeld DK, Bokemeyer C: A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).Lung Cancer 57(2), 181-186 (2007)

Thöm I, Schult-Kronefeld O, Burkholder I, Goern M, Andritzky B, Blonski K, Kugler C, Edler L, Bokemeyer C, Schumacher U, Laack E: Lectin histochemistry of metastatic adenocarcinomas of the lung.Lung Cancer 56(3), 391-397 (2007)